ReviewNature reviews. Endocrinology2022
Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer.
Review in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 52 citations in OpenAlex.
- Cumulative effects of lifelong systemic excess growth hormone on postcranial skeletal morphology in adult mice.Journal of anatomy · 2026Article
- Identification of serum biomarkers linking myocardial fibrosis, systolic dysfunction and outcomes in patients with severe aortic stenosis.Cardiovascular research · 2026Article
- Growth hormone receptor antagonism improves tumoral chemo-immunotherapy response in a mouse model of lung cancer.Translational oncology · 2026Article
- Cardiovascular Implications of the Enhanced Games: Performance Enhancing Drugs in Competition and Recreation.Sports medicine - open · 2026Review
- Growth Hormone, Not Simply Just a Hormone for Growth.Endocrinology and metabolism (Seoul, Korea) · 2026Review
- GH Alters Lymphatic Vessels in Female Mice and STAT5 Phosphorylation in Human Lymphatic Endothelial Cells.Endocrinology · 2026Article
- Impact of Nutrition on Somatotroph Axis: A Potential Role in Acromegaly and Its Cardiovascular Risk?Journal of the Endocrine Society · 2026Review
- Targeting Growth Hormone Receptor to Overcome Therapy Resistance in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2025Article
- Growing Pains: GH-induced Fibrosis Across Multiple Organs in bGH Mice.Endocrinology · 2025Article
- Sex-Specific transcriptomic changes in adipose tissue following adult-onset disruption of growth hormone receptor.Pituitary · 2025Article
- The 20 kDa isoform of the human growth hormone variant alters adipose and muscle gene expression differently than human growth hormone.Journal of neuroendocrinology · 2025Article
- Bioinformatics and experimental animal model reveal the prognostic value of immunogenic cell death-related proteins in idiopathic pulmonary fibrosis.Journal of thoracic disease · 2025Article
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- Article
- A high-fat diet suppresses growth hormone synthesis and secretion by influencing the Vit D receptor and Pit1.Endocrine · 2025Article
- Growth Hormone Signaling in Bladder Cancer: Transcriptomic Profiling of Patient Samples and In Vitro Evidence of Therapy Resistance via ABC Transporters and EMT Activation.International journal of molecular sciences · 2025Article
- Liver-specific actions of GH and IGF1 that protect against MASLD.Nature reviews. Endocrinology · 2025 · on this mapReview
- Risk Factors Involved in the Blood (Leukocyte-Depleted Suspended Red Blood Cells and Plasma) Transfusion During Glioma Operations.Journal of blood medicine · 2025Article
- Recombinant human growth hormone and brain neoplasm association: a pharmacovigilance and Mendelian randomization analysis based on US FAERS, Japanese JADER, and Canadian CVARD.Frontiers in pharmacology · 2025Article
- Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.International journal of medical sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Since its discovery nearly a century ago, over 100,000 studies of growth hormone (GH) have investigated its structure, how it interacts with the GH receptor and its multiple actions. These include effects on growth, substrate metabolism, body composition, bone mineral density, the cardiovascular system and brain function, among many others. Recombinant human GH is approved for use to promote growth in children with GH deficiency (GHD), along with several additional clinical indications. Studies of humans and animals with altered levels of GH, from complete or partial GHD to GH excess, have revealed several covert or hidden actions of GH, such as effects on fibrosis, cardiovascular function and cancer. In this Review, we do not concentrate on the classic and controversial indications for GH therapy, nor do we cover all covert actions of GH. Instead, we stress the importance of the relationship between GH and fibrosis, and how fibrosis (or lack thereof) might be an emerging factor in both cardiovascular and cancer pathologies. We highlight clinical data from patients with acromegaly or GHD, alongside data from cellular and animal studies, to reveal novel phenotypes and molecular pathways responsible for these actions of GH in fibrosis, cardiovascular function and cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.